Carcinoid syndrome is caused by carcinoid tumors secreting particular harmful chemicals. Carcinoid syndrome can occur as a consequence of infections or other disorders, as well as medical or surgical treatments such as chemotherapy, tumor debulking, anesthesia, and embolization. Diarrhea and flushing of the skin, as well as a bronchoconstriction and rapid heartbeat, are all common signs of the syndrome. If left untreated, it can lead to asthma, electrolyte imbalance, irritable bowel disease, dehydration, menopause, and weight loss.
Get a Sample Copy of the Report 2021 @
https://www.coherentmarketinsights.com/insight/request-sample/1216
For instance, according to a study published in the Journal of Clinical Oncology in 2009, 4 to 5 people out of every 100,000 are diagnosed with a neuroendocrine tumor, and around 100,000 people in the U.S. suffer from neuroendocrine tumors. Most people with carcinoid are asymptomatic till the tumor is completely formed. On a patient-by-patient basis, treatment options such as chemoembolization, chemotherapy, radiofrequency ablation, surgery, and targeted radionuclide therapy may be considered to overcome the carcinoid crisis. Since carcinoid syndrome is such a rare condition, there are limited treatment options available. As a result, market players have a lot of cash to invest with. As a result, market players have an attractive opportunity in the global carcinoid syndrome diarrhea treatment market.
Lexicon Pharmaceutical Inc. announced that, the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in adults in combination with somatostatin analogue therapy (SSA) in February 2017. Xermelo lowers the frequency of carcinoid syndrome diarrhea by targeting the overproduction of serotonin hormone inside mNET cells. Moreover, in 2017, Ipsen Biopharmaceutical received the U.S. Food and Drug Administration (FDA) clearance for a supplementary indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, with the purpose of reducing the use of short-acting somatostatin analogue rescue therapy.
The development of a first-of-its-kind treatment method to treat carcinoid syndrome diarrhea offers market players with extremely profitable growth opportunities. The global carcinoid syndrome diarrhea treatment market is predicted to be restricted by lack of information and particular side effects associated with this therapy.
Ask for PDF sample copy of the report @
https://www.coherentmarketinsights.com/insight/request-pdf/1216
Rising prevalence of rare carcinoid syndrome diarrhea is expected to propel the global carcinoid syndrome diarrhea treatment market growth.
According to the National Organization for Rare Disorders (NORD), around 27 people per million people in the U.S. are identified with carcinoid tumors each year, with only 10% of those diagnosed developing carcinoid syndrome. Furthermore, it affects both men and women in about similar numbers. As the disease becomes more common, so does the demand for carcinoid syndrome diarrhea treatment devices. As a result, the carcinoid syndrome diarrhea treatment market is expected to grow.
Some of the major players functioning in the global carcinoid syndrome diarrhea treatment market include BTG International Ltd., Novartis International AG (Sandoz), Omega Laboratories Limited., Ipsen Biopharmaceuticals Inc., Teva Pharmaceutical Industries Limited., Pharmascience Inc., Sirtex Medical Ltd., Lexicon Pharmaceuticals Inc., and Mylan N.V
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1216
Table of Content
Global Carcinoid Syndrome Diarrhea Treatment Market Research Report
Section 1: Global Carcinoid Syndrome Diarrhea Treatment Industry Overview
Section 2: Global Economic Impact on Carcinoid Syndrome Diarrhea Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Carcinoid Syndrome Diarrhea Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Carcinoid Syndrome Diarrhea Treatment Market Forecast
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837